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CLINICAL SCIENCE
Efficacy of Amniotic Membrane Transplantation for the
Treatment of Corneal Ulcers
Kaspar Schuerch, MD, Andrea Baeriswyl, Beatrice E. Frueh, MD, and Christoph Tappeiner, MD
Purpose: To evaluate the outcome of amniotic membrane trans-
plantation (AMTX) as a treatment for corneal ulcers.
Methods: Patients treated with AMTX for refractory corneal ulcers
between 2012 and 2017 were evaluated in a retrospective analysis.
Primary outcome measure was complete reepithelialization.
Results: A total of 149 patients were included (mean age 68 6 18
years). The mean duration between ulcer onset and AMTX was 426
46 days. The longest time between ulcer diagnosis and AMTX was
found in bacterial ulcers and the shortest time to AMTX in eyes with
trauma/chemical burns (mean 65 6 15 days and 14 6 4 days,
respectively). In 70% of the patients, a single AMTX procedure was
sufficient to achieve epithelial closure (21% ,1 month, 40% within
1 –3 months, and 9% within 3–6 months). Treatment failure was
observed in 30% of all patients, and most of them underwent further
interventions. Highest closure rates were found in bacterial ulcers,
herpetic ulcers, and neurotrophic ulcers (80%, 85%, and 93%,
respectively), whereas the lowest reepithelialization rates were found
in ulcers after corneal surgery and ulcers associated with rheumatic
disease (52% and 57%, respectively).
Conclusions: AMTX is a valuable treatment option to achieve
corneal epithelial wound healing in cases refractory to conventional
treatment. Success rates differ depending on the etiology of ulcer.
Key Words: amniotic membrane, corneal ulcer, corneal disease,
cornea, amniotic membrane transplantation, ocular surface disease
(Cornea 2019;00:1–5)
The initial event leading to a corneal epithelial defect thatprogresses to ulceration is the breakdown of the corneal
epithelial surface.1,2 A corneal epithelial defect may be
caused by exogenous factors such as infection, ocular xerosis,
trauma, or chemical burn. On the other hand, it may be
because of endogenous conditions such as exposure to
keratitis or neurotrophic keratitis, keratomalacia, or recurrent
corneal erosions.3 When associated with excessive inflam-
mation or failure of the normal corneal healing response, the
epithelial breakdown may eventually progress into a persistent
corneal ulcer.4 Because of further corneal melting, such ulcers
may end in a descemetocele or even in corneal perforation.
All of these situations bear a high risk of potentially
irreversible visual loss.1
Because etiologies of corneal ulcers may vary, early
diagnosis and appropriate medical treatment are crucial.3 To
further support epithelial healing in cases refractory to local
medical therapy, the use of bandage contact lenses,5 surgical
approaches such as conjunctival flaps6 or tarsorraphy,7 and
eventually systemic immunosuppressive/-modulatory treat-
ment8 are established treatment options. Transplantation of
amniotic membranes (AMTX) has been shown to be a prom-
ising surgical procedure that is helpful to reconstruct the ocular
surface by supporting the epithelialization of the cornea.4,9,10 In
corneal ulcers resistant to aforementioned therapies, AMTX
may help to prevent or stop corneal melting and eventually
even avoid the need for an emergency keratoplasty.11
AMTX for ocular surface treatment was first described
by de Rötth12 and Sorsby.13,14 In 1995, Kim and Tseng15
developed a method of preserving amniotic membranes using
glycerine. Since then, AMTX has been used to treat various
ophthalmologic diseases.4,16–19
An amniotic membrane consists of a thick basement
membrane and an avascular stroma that contains a high
concentration of basic fibroblast growth factors.20 It also
represents a mechanical barrier for frictional forces.21 Fur-
thermore, amniotic membranes promote epithelial recovery
and suppress inflammation because of the contained cyto-
kines22,23 and growth factors.9 In addition, they may also
have protective antimicrobial properties.21 It has been shown
that amniotic membranes have antiinflammatory24 and anti-
angiogenic properties.25
The aim of this study was to evaluate the outcome of
amniotic membrane transplantation in a large cohort of
patients with corneal ulcers.
METHODS
This is a retrospective analysis of consecutive patients
who underwent AMTX because of treatment-refractory corneal
ulcers at the Department of Ophthalmology, Inselspital Bern
University Hospital, University of Bern, Switzerland, be-
tween 2012 and 2017. Data collection consisted of findings
obtained from the clinical history and ophthalmic examination.
All patients underwent a clinical examination before sur-
gery, including the assessment of best corrected visual acuity
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(BCVA) and slit lamp examination. The minimum follow-up
period was 6 months. The indication for AMTX was non-
healing corneal ulcers that were considered refractory to
medical treatment, defined as not showing any tendency of
epithelial healing despite adequate conventional treatment of the
ocular surface (eg, artificial eye tears, ointments, and bandage
contact lens) and the underlying etiologies (eg, antiherpetic
treatment, oculoplastic surgery in case of lagophthalmos or any
other eyelid problems, and systemic corticosteroid and/or
immunomodulating treatment in rheumatic disease). All con-
secutive patients undergoing AMTX between 2012 and 2017
and fulfilling these criteria were included in the study. Patients
with a loss of follow-up after AMTX were excluded from
the study.
The impact of the following parameters on the outcome
was evaluated: ulcer etiology and duration between ulcer onset
and surgery, ulcer size (measured as a fluorescein staining
positive area at the slit lamp in mm2), corneal neovasculariza-
tion, and BCVA(LogMAR) at baseline (defined as the last visit
before AMTX).
Amniotic membranes were obtained from human pla-
centas shortly after elective caesarean delivery and were
prepared under sterile conditions. Maternal blood was screened
for human immunodeficiency virus types 1 and 2, hepatitis
virus types B and C, and syphilis. After preparation and
fixation onto a sterile sponge, amniotic membranes were stored
in a 15-mL conservation medium (50% glycerol/Dulbecco's
Modified Eagle's medium [DMEM] + 0.2% antibiotic-anti-
mycotic [100X solution containing penicillin, amphotericin B,
streptomycin; Thermo Fisher Scientific, Waltham, MA]) at
270°C. Surgery was performed mainly under topical and in
selected cases using general anesthesia, based on the preference
of the patients. During the surgical procedure, an amniotic
membrane was placed with the epithelium up within the
corneal epithelial defect and fixed using nylon 10-0 interrupted
sutures. A second amniotic membrane with the epithelium
down was placed overlapping the first layer and over the whole
cornea and fixed with a continuous nylon 10-0 suture to the
conjunctiva. This technique was previously described in
detail.4 A therapeutic contact lens was placed over both
amniotic membranes at the end of the surgery. Patients were
treated with preservative-free topical artificial tears and
antibiotic drops. The continuous suture was removed after
resorption of the upper amniotic membrane; the single sutures
of the deeper amniotic membrane and the contact lens were
removed after integration/resorption/loss of the deeper amni-
otic membrane layer and/or full reepithelialization.
Treatment success was defined as complete corneal
reepithelialization within 6 months after the intervention (ie,
the absence of any fluorescein staining at the slit lamp
examination during the follow-up).
Means and SDs were reported using descriptive statis-
tics. The impact of ulcer etiology and duration between ulcer
onset and surgery, ulcer size (area in mm2), corneal neo-
vascularization, and BCVA at baseline on epithelial closure
(success) were assessed with a logistic regression model with
post hoc Wald testing.
A one-way analysis of variance for multiple comparisons
was used to compare time with AMTX and epithelial closure
times between the groups. A paired Student t test was used to
analyze the preoperative and postoperative visual acuity for the
whole cohort. For subgroup comparisons of BCVA, multiple t
tests with a Holm–Sidak correction were used. Statistical analysis
was performed using GraphPad Prism software (Version 8.0.1,
San Diego, CA) and IBM SPSS Statistics (Version 25, IBM,
Armonk, NY). A P-value ,0.05 was considered as significant.
The retrospective study was approved by the local
ethics committee and was performed in accordance with the
Declaration of Helsinki.
RESULTS
A total of 149 eyes of 149 patients undergoing AMTX
for a nonhealing corneal ulcer between 2012 and 2017 were
included in this study. The mean age at AMTX was 68 years
(SD 618, range 2–95 years). In most eyes (138 eyes, 93%),
a double-layered AMTX was performed, whereas in 11 eyes
(7%) a multilayer technique was chosen to fill deep-ulcers
with the first amnion layers. For the outcome analysis,
patients were divided into 8 subgroups according to the
etiology of ulcer: group 1: herpetic ulcers; group 2: ulcers
associated with rheumatic disease; group 3: ulcers after
previous penetrating keratoplasty (PK) or other corneal
surgery; group 4: bacterial ulcers; group 5: limbal stem cell
insufficiency due to chemical burn or trauma; group 6: ulcers
due to bullous keratopathy as a complication after ocular
surgery other than PK; group 7: ulcers due to lagophthalmos;
and group 8: neurotrophic ulcers (Table 1).
Time to AMTX
The mean duration from the diagnosis of the corneal
ulcer to AMTX was 42 6 46 days. In bacterial ulcers, a mean
of 65 days was waited until AMTX, whereas in patients with
trauma or chemical burns, AMTX was performed after a mean
of only 14 days (Table 1). Time from ulcer diagnosis to
AMTX did not reveal any significant difference between the
subgroups (P . 0.05).
Epithelial Closure After AMTX
In 70% (n = 105) of eyes, a single AMTX procedure
was able to achieve closure of the corneal defect. Among
these patients, epithelial closure was observed in 21% (n =
32) within the first month, in further 40% (n = 60) within 1 to
3 months, and in 9% of patients (n = 13) within 3 to 6 months
after AMTX. However, no epithelial closure was achieved in
the remaining 30% of patients (n = 44) (Table 2).
Ulcers due to bullous keratopathy, bacterial ulcers,
herpetic ulcers, and neurotrophic ulcers had the highest
overall closure rates (79%, 80%, 85%, and 93%, respectively)
and achieved epithelial closure mainly within the first 3
months after surgery. Ulcers in patients with rheumatic
disease and with ulcers due to wound-healing problems after
corneal surgery revealed the lowest closure rates (52% and
57%, respectively). Both, ulcers due to chemical burns or
trauma and ulcers due to lagophthalmos, revealed closure
rates of 63%. The success rate was significantly better in
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herpetic ulcers compared with ulcers associated with rheu-
matic disease and ulcers after corneal surgery (P = 0.011 and
P = 0.017, respectively). In addition, neurotrophic ulcers
revealed a higher reepithelialization rate than that of ulcers
associated with rheumatic disease (P = 0.022). No significant
difference was observed between all other subgroups.
Time to epithelial closure was significantly slower in
ulcers due to bullous keratopathy than that in neurotrophic
ulcers (P = 0.01), ulcers after corneal surgery (P = 0.007),
ulcers after chemical burn or trauma (P = 0.006), and ulcers
associated with rheumatic disease (P = 0.02). All other
subgroups did not differ significantly between each other in
epithelial closure time (Figure 1).
The duration between ulcer onset and surgery, ulcer
size (area in mm2, mean 20.3 mm2, and SD 29 mm2),
presence of corneal neovascularization (n = 95), and BCVA at
baseline did not reveal to have any significant impact on the
epithelial closure success rate (ie, AMTX success vs. failure)
in our patients (P . 0.05, each).
Treatment Failure of AMTX
Because of treatment failure, 42 secondary surgical
procedures in 44 eyes with AMTX had to be performed to
achieve epithelial closure. A second AMTX was performed
whether there was still a realistic chance for epithelial healing.
In cases with a high risk of perforation despite the first AMTX
or in which perforation already had occurred, PK was
performed. If the eye did not have a favorable visual prognosis
TABLE 1. Etiology of Corneal Ulcers Treated With AMTX (N = 149 Eyes)
N (M/F) Age at AMTX, yr (mean 6 SD) Time to AMTX, d (mean 6 SD)
Herpetic ulcers 33 (14/19) 72 6 9 49 6 9
Ulcers associated with rheumatic disease 23 (11/12) 72 6 9 34 6 8
Previous PK or other corneal surgery 30 (9/21) 67 6 8 50 6 9
Bacterial ulcers 10 (6/4) 62 6 8 65 6 15
Ulcers in limbal stem cell insufficiency due to chemical
burn or trauma
16 (2/14) 53 6 8 14 6 4
Ulcers due to bullous keratopathy, as a complication
after ocular surgery other than PK
14 (6/8) 76 6 9 31 6 8
Lagophthalmos 8 (3/5) 63 6 8 52 6 10
Neurotrophic ulcers 15 (7/8) 75 6 9 46 6 10
M, male; F, female.
TABLE 2. Epithelial Closure in the Subgroups of Eyes With
AMTX (N = 149 Eyes)
Success Failure
Total
Closure
Rate (%)
,1
mo
(%)
1–3
mo
(%)
3–6
mo
(%)
Treatment
Failure
(%)
Herpetic ulcers 84.8 30.3 39.4 15.2 15.2
Ulcers associated with
rheumatic disease
52.2 13.0 39.1 0.0 47.8
Previous PK or other
corneal surgery
56.7 16.7 40.0 0.0 43.3
Bacterial ulcers 80.0 20.0 50.0 10.0 20.0
Ulcers in limbal stem cell
insufficiency due to
chemical burn or
trauma
62.5 25.0 37.5 0.0 37.5
Ulcers due to bullous
keratopathy, as a
complication after
ocular surgery other
than PK
78.6 0.0 42.9 35.7 21.4
Lagophthalmos 62.5 12.5 37.5 12.5 37.5
Neurotrophic ulcers 93.3 46.7 40.0 6.7 6.7
Total 70.5 21.5 40.3 8.7 29.5
FIGURE 1. Epithelial closure time. Box and whiskers plot for all
epithelial closure times in the subgroups. The boxes show 25
and 75 percentiles and the median. The whiskers
depict minimum and maximum values. Statistically significant
results using the analysis of variance for multiple comparisons
are indicated with *(P , 0.05).
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and was very painful, conjunctival flap surgery or even
evisceration was discussed with the patient. In 2 eyes, epithelial
closure was observed 192 and 202 days after the first AMTX
(ie, defined as AMTX failure). In 10 eyes, a third procedure
was necessary. In only one eye, the third AMTX failed to close
the epithelial defect in an ulcer associated with rheumatic
disease; therefore, ultimately, PK was performed (Figure 2).
Visual Acuity Outcome
At baseline, no statistically significant difference in
BCVA between the subgroups could be found, except ulcers
associated with rheumatic disease with a better BCVA
compared with ulcers in bullous keratopathy (P = 0.02). When
analyzing the BCVA for every subgroup at baseline versus the
last follow-up (or at the visit before secondary intervention in
cases of AMTX failure with further surgery), no statistically
significant change was found (P . 0.05, each; Figure 3).
However, for the whole cohort of patients, BCVA improved
significantly from a mean of 1.8 6 0.6 LogMAR at baseline to
a mean of 1.6 6 0.8 LogMAR (measured at the time-point of
the last follow-up or at the last visit before secondary surgical
interventions in eyes with AMTX treatment failure undergoing
further surgeries) (P = 0.002).
DISCUSSION
Our results reveal an overall AMTX success rate of
70% in our study population. In most patients, epithelial
closure was achieved within the first 3 months after AMTX.
Success rates in our patients varied depending on the
etiological subgroup.
In nearly 50% of all patients with ulcers associated with
rheumatic disease or due to wound-healing problems after
corneal surgery, epithelial closure was not achieved with
AMTX. Furthermore, these subgroups revealed a significantly
lower epithelial healing rate than those with herpetic ulcers. In
ulcers associated with rheumatic disease, this might be
because of severe and aggressive corneal inflammation and
melting. In ulcers after corneal surgery, epithelial healing is
often delayed because of multifactorial etiologies such as
neurotrophic problems and endothelial failure inhibiting
corneal reepithelialization.
Most of the previous publications on AMTX are case
reports, case series, and reports on AMTX in patients for
selected underlying etiologies.4,9–11,16,20,21,26,27 In those
studies, recurrence rates of 10% to 29% after AMTX were
reported.4,28 These results are slightly lower than our
findings that showed an AMTX failure rate of 30%.
Moreover, our study showed that there is a significant
difference in the success rate between different etiological
subgroups, with herpetic ulcers having a significantly higher
success rate than ulcers after PK and ulcers associated with
rheumatic disease. In addition, neurotrophic ulcers showed
a higher success rate after AMTX than ulcers associated
with rheumatic disease.
In previous studies, BCVA did not reveal any
significant improvement or worsening in the mid/long
term.25,28,29 Although AMTX leads to opacification of the
corneal surface in the initial phase, the amniotic membrane
FIGURE 2. Flowchart of success and
failures after AMTX.
FIGURE 3. Bar chart of BCVA in LogMAR at baseline and at the
last follow-up (or at the visit before a secondary intervention in
cases of AMTX failure with further surgery). Baseline was
defined as BCVA at the last visit before AMTX. No statistically
significant difference between the preoperative and post-
operative values was found in the subgroups’ analyses.
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dissolves after a few weeks. Indeed, AMTX may even lead
to an improvement of visual acuity through corneal surface
restoration.4 In addition, in our study, such an improvement
was seen, when analyzing the whole cohort of patients.
However, this could not be shown in the subgroups’
analyses, probably because of the lower power of the
smaller sample size.
Our study has limitations because of the retrospective
nature of our analysis and the lack of a control group. Another
limitation is the lack of optical coherence tomography data to
quantify the depth of ulcers. In a clinical slit-lamp examina-
tion, descemetocele was observed in only 2 patients before
surgery (one patient in the subgroup of ulcers due to bullous
keratopathy and one patient within the subgroup of herpetic
ulcers). Furthermore, our comparative analytical results
should be read with caution, as a potential bias cannot be
fully excluded in a noncontrolled retrospective study. On the
other hand, our study provides interesting data on a large
patient cohort with a variety of different subgroups and
information on epithelial closure time.
In conclusion, in this study, we show significant differ-
ences in corneal epithelial healing (success rates and time to
epithelial closure) after AMTX depending on the underlying
etiology, with the best success in patients with neurotrophic
ulcers and the worst epithelial closure rates in patients with
ulcers associated with rheumatic disease. Future prospective
studies with a standardized follow-up are desirable to further
investigate epithelial healing dynamics after AMTX.
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